Michael J. Tomsicek

2017 - CRISPR Therapeutics AG

In 2017, Michael J. Tomsicek earned a total compensation of $2.2M as Chief Financial Officer at CRISPR Therapeutics AG.

Compensation breakdown

Bonus$50,000
Non-Equity Incentive Plan$23,987
Option Awards$2,035,542
Salary$51,885
Total$2,161,414

Tomsicek received $2M in option awards, accounting for 94% of the total pay in 2017.

Tomsicek also received $50K in bonus, $24K in non-equity incentive plan and $51.9K in salary.

Rankings

In 2017, Michael J. Tomsicek's compensation ranked 5,142nd out of 14,666 executives tracked by ExecPay. In other words, Tomsicek earned more than 64.9% of executives.

ClassificationRankingPercentile
All
5,142
out of 14,666
65th
Division
Manufacturing
1,830
out of 5,772
68th
Major group
Chemicals And Allied Products
545
out of 2,075
74th
Industry group
Drugs
420
out of 1,731
76th
Industry
Biological Products, Except Diagnostic Substances
78
out of 313
75th
Source: SEC filing on April 30, 2019.

Tomsicek's colleagues

We found four more compensation records of executives who worked with Michael J. Tomsicek at CRISPR Therapeutics AG in 2017.

2017

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2017

Tony Ho

CRISPR Therapeutics AG

EVP, Research and Development

2017

Rodger Novak

CRISPR Therapeutics AG

President

2017

James Kasinger

CRISPR Therapeutics AG

General Counsel

News

In-depth

You may also like